Automated checks run on every build (contradictions, sourcing and hygiene) and weekly against the outside world (openFDA labels, ClinicalTrials.gov, and every cited URL). Findings are candidates for review, not verdicts; confirmed errors go to the corrections log.
Computed from the corpus alone: status fields that disagree with approval records or the six-region table, positive trials whose primary hazard ratio is not below 1, records last checked before their latest regulatory event, standard-of-care and roadmap rows citing withdrawn items, and future years.
| Entity | Detail | |
|---|---|---|
| MOUNTAINEER-03 | trial | yearReported 2027 is in the future |
| Entity | Detail | |
|---|---|---|
| Breast cancer (all types) | cancer | standard-of-care row "Treating less than the whole breast" cites NSABP B-39/RTOG 0413 (status negative) without saying so in the text; explain the negative result or drop the reference |
| Breast cancer (all types) | cancer | standard-of-care row "Radiotherapy after mastectomy, and to the nodes" cites NSABP B-51 / RTOG 1304 (status negative) without saying so in the text; explain the negative result or drop the reference |
| Colorectal cancer | cancer | standard-of-care row "Stage III colon cancer, mismatch-repair proficient" cites Alliance N0147 (status negative) without saying so in the text; explain the negative result or drop the reference |
| Colorectal cancer | cancer | standard-of-care row "Peritoneal metastases" cites PROPHYLOCHIP-PRODIGE 15 (status negative) without saying so in the text; explain the negative result or drop the reference |
| Colorectal cancer | cancer | standard-of-care row "The failed and stopped programmes" cites Alliance N0147 (status negative) without saying so in the text; explain the negative result or drop the reference |
| Colorectal cancer | cancer | standard-of-care row "The failed and stopped programmes" cites PROPHYLOCHIP-PRODIGE 15 (status negative) without saying so in the text; explain the negative result or drop the reference |
| Corticotroph pituitary neuroendocrine tumour (Cushing disease and silent corticotroph tumour) | cancer | standard-of-care row "Persistent or recurrent" cites Mifepristone (status negative) without saying so in the text; explain the negative result or drop the reference |
| Extensive-stage small-cell lung cancer | cancer | standard-of-care row "Brain" cites Takahashi trial: prophylactic cranial irradiation with MRI surveillance in extensive-stage small-cell lung cancer (status negative) without saying so in the text; explain the negative result or drop the reference |
| Lung cancer (all types) | cancer | standard-of-care row "Extensive-stage small-cell lung cancer, first line" cites Takahashi trial: prophylactic cranial irradiation with MRI surveillance in extensive-stage small-cell lung cancer (status negative) without saying so in the text; explain the negative result or drop the reference |
| Lung cancer (all types) | cancer | standard-of-care row "Relapsed small-cell lung cancer" cites ATLANTIS (status negative) without saying so in the text; explain the negative result or drop the reference |
| Pancreatic ductal adenocarcinoma | cancer | standard-of-care row "The failed or stopped programmes" cites AMPLIFY-7P (status negative) without saying so in the text; explain the negative result or drop the reference |
| PDGFRA D842V-mutant GIST | cancer | standard-of-care row "Progression on avapritinib" cites VOYAGER (status negative) without saying so in the text; explain the negative result or drop the reference |
| Poorly differentiated chordoma (SMARCB1-deficient) | cancer | standard-of-care row "All cases" cites Tazemetostat (status withdrawn) without saying so in the text; explain the negative result or drop the reference |
| Prostate cancer | cancer | standard-of-care row "Screening" cites PLCO, prostate component (Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial) (status negative) without saying so in the text; explain the negative result or drop the reference |
| Prostate cancer | cancer | standard-of-care row "Hormone-relapsed (castration-resistant) metastatic prostate cancer: the order the approved treatments are given in" cites FIRSTANA (status negative) without saying so in the text; explain the negative result or drop the reference |
| Prostate cancer | cancer | standard-of-care row "Combinations and strategies that were tested and abandoned" cites READY (status negative) without saying so in the text; explain the negative result or drop the reference |
| Triple-negative breast cancer (TNBC) | cancer | standard-of-care row "Residual disease after chemotherapy: capecitabine or olaparib" cites ECOG-ACRIN EA1131 (status negative) without saying so in the text; explain the negative result or drop the reference |
| Triple-negative breast cancer (TNBC) | cancer | standard-of-care row "Residual disease after chemotherapy: capecitabine or olaparib" cites BRE12-158 (Hoosier Oncology Group) (status negative) without saying so in the text; explain the negative result or drop the reference |
| Entity | Detail | |
|---|---|---|
| Atezolizumab | drug | EU first approval year 2019 in approvals but 2017 in regional-approvals.ts |
| Atezolizumab | drug | UK first approval year 2020 in approvals but 2017 in regional-approvals.ts |
| Catumaxomab | drug | EU first approval year 2009 in approvals but 2025 in regional-approvals.ts |
| Denosumab | drug | EU first approval year 2011 in approvals but 2010 in regional-approvals.ts |
| Durvalumab | drug | UK first approval year 2024 in approvals but 2018 in regional-approvals.ts |
| Erlotinib | drug | EU first approval year 2007 in approvals but 2005 in regional-approvals.ts |
| Futibatinib | drug | UK first approval year 2024 in approvals but 2023 in regional-approvals.ts |
| Ivosidenib | drug | UK first approval year 2024 in approvals but 2023 in regional-approvals.ts |
| Larotrectinib | drug | UK first approval year 2020 in approvals but 2019 in regional-approvals.ts |
| Olaparib | drug | EU first approval year 2019 in approvals but 2014 in regional-approvals.ts |
| Olaparib | drug | UK first approval year 2023 in approvals but 2014 in regional-approvals.ts |
| Pembrolizumab | drug | EU first approval year 2021 in approvals but 2015 in regional-approvals.ts |
| Pembrolizumab | drug | UK first approval year 2022 in approvals but 2015 in regional-approvals.ts |
| Sacituzumab govitecan | drug | UK first approval year 2022 in approvals but 2021 in regional-approvals.ts |
| Talazoparib | drug | UK first approval year 2024 in approvals but 2019 in regional-approvals.ts |
| Trastuzumab deruxtecan | drug | EU first approval year 2023 in approvals but 2021 in regional-approvals.ts |
| Trastuzumab deruxtecan | drug | UK first approval year 2024 in approvals but 2021 in regional-approvals.ts |
| Abemaciclib | drug | regional-approvals.ts records EU approved 2018 but approvals[] has no EU row |
| Abiraterone acetate | drug | regional-approvals.ts records EU approved 2011 but approvals[] has no EU row |
| Acalabrutinib | drug | regional-approvals.ts records EU approved 2020 but approvals[] has no EU row |
| Alectinib | drug | regional-approvals.ts records EU approved 2017 but approvals[] has no EU row |
| Alpelisib | drug | regional-approvals.ts records EU approved 2020 but approvals[] has no EU row |
| Apalutamide | drug | regional-approvals.ts records EU approved 2019 but approvals[] has no EU row |
| Asciminib | drug | regional-approvals.ts records EU approved 2022 but approvals[] has no EU row |
| Avelumab | drug | regional-approvals.ts records EU approved 2017 but approvals[] has no EU row |
| Axicabtagene ciloleucel | drug | regional-approvals.ts records EU approved 2018 but approvals[] has no EU row |
| Axitinib | drug | regional-approvals.ts records EU approved 2012 but approvals[] has no EU row |
| Azacitidine | drug | regional-approvals.ts records EU approved 2008 but approvals[] has no EU row |
| Binimetinib | drug | regional-approvals.ts records EU approved 2018 but approvals[] has no EU row |
| Blinatumomab | drug | regional-approvals.ts records EU approved 2015 but approvals[] has no EU row |
| Entity | Detail | |
|---|---|---|
| Abemaciclib | drug | asOf 2026-09-04 predates the approval dated 2026-09-18 (US): With imlunestrant, for ER-positive, HER2-negative, ESR1-mutated advanced or meta |
| Belzutifan | drug | asOf 2026-09-04 predates the approval dated 2026-09-24 (US): With lenvatinib, advanced renal cell carcinoma with a clear cell component |
| Galleri | drug | asOf 2026-09-04 predates the advisory-committee dated 2026-09-23 (US): FDA Molecular and Clinical Genetics Panel meeting |
| Imlunestrant | drug | asOf 2026-09-07 predates the approval dated 2026-09-18 (US): With abemaciclib, for ER-positive, HER2-negative, ESR1-mutated advanced or metas |
| Lenvatinib | drug | asOf 2026-09-07 predates the approval dated 2026-09-24 (US): With belzutifan, advanced renal cell carcinoma with a clear cell component |
| Lirafugratinib | drug | asOf 2026-09-11 predates the approval dated 2026-09-23 (US): Previously treated unresectable, locally advanced or metastatic cholangiocarcino |
| Sevabertinib | drug | asOf 2026-09-06 predates the accelerated-approval dated 2026-09-09 (US): FDA grants accelerated approval to sevabertinib for locally advanced or metastat |
| Entity | Detail | |
|---|---|---|
| Advanced melanoma (unresectable stage III and stage IV) | cancer | pipeline lists Fianlimab + cemiplimab phase 3 (first-line melanoma) (status negative) |
| Early hepatocellular carcinoma (BCLC 0 and A) | cancer | pipeline lists IMbrave050 (status negative) |
| Endometrial cancer with no specific molecular profile | cancer | pipeline lists XPORT-EC-042 / ENGOT-EN20 / GOG-3083 (status negative) |
| Epithelioid sarcoma | cancer | pipeline lists Tazemetostat with doxorubicin as front-line therapy for advanced epithelioid sarcoma (EZH-301 run-in) (status withdrawn) |
| Epithelioid sarcoma | cancer | pipeline lists Tazemetostat (status withdrawn) |
| Mesothelioma | cancer | pipeline lists Anetumab ravtansine (status negative) |
| Mesothelioma | cancer | pipeline lists Anetumab ravtansine versus vinorelbine in relapsed mesothelin-positive pleural mesothelioma (status negative) |
| Oropharyngeal cancer (tonsil and base of tongue) | cancer | pipeline lists De-ESCALaTE HPV (status negative) |
| Resectable pancreatic ductal adenocarcinoma | cancer | pipeline lists AMPLIFY-7P (status negative) |
| Stage III melanoma (after surgery) | cancer | pipeline lists RELATIVITY-098 (status negative) |
| Entity | Detail | |
|---|---|---|
| EORTC 22881-10882 (boost against no boost) | trial | status positive but primary endpoint hazard ratio 1.05 (Overall survival at 20 years); not described as a non-inferiority or de-escalation trial |
| NSABP B-32 | trial | status positive but primary endpoint hazard ratio 1.2 (Overall survival at 8 years (sentinel node-negative patients)); not described as a non-inferiority or de-escalation trial |
| RTOG 94-08 | trial | status positive but primary endpoint hazard ratio 1.17 (Overall survival at 10 years); not described as a non-inferiority or de-escalation trial |
| SEQUOIA | trial | status positive but primary endpoint hazard ratio 1.045 (Overall survival); not described as a non-inferiority or de-escalation trial |
| TRIANGLE | trial | status positive but primary endpoint hazard ratio 1.77 (Failure-free survival at 3 years, arm A against arm I (superiority of transplant not shown)); not described as a non-inferiority or de-escalation trial |
| Entity | Detail | |
|---|---|---|
| 131I-MIBG (iobenguane I-131) therapy | drug | US/EU approvals recorded (US 2018) but status is "established" |
| Alitretinoin | drug | US/EU approvals recorded (US 1999) but status is "established" |
| Altretamine | drug | US/EU approvals recorded (US 1990) but status is "established" |
| Choline C-11 | drug | US/EU approvals recorded (US 2012) but status is "established" |
| Cinacalcet | drug | US/EU approvals recorded (US 2004) but status is "established" |
| Dolasetron | drug | US/EU approvals recorded (US 1997) but status is "established" |
| Dronabinol | drug | US/EU approvals recorded (US 1985) but status is "established" |
| Eltrombopag | drug | US/EU approvals recorded (US 2008) but status is "established" |
| Emapalumab | drug | US/EU approvals recorded (US 2018) but status is "established" |
| Estramustine | drug | US/EU approvals recorded (US 1981) but status is "established" |
| Ethiodized oil | drug | US/EU approvals recorded (US 1954) but status is "established" |
| Floxuridine | drug | US/EU approvals recorded (US 1970) but status is "established" |
| Fostamatinib | drug | US/EU approvals recorded (US 2018) but status is "established" |
| Methoxsalen (extracorporeal photopheresis) | drug | US/EU approvals recorded (US 1999) but status is "established" |
| Methyl aminolevulinate | drug | US/EU approvals recorded (US 2004) but status is "established" |
| Nabilone | drug | US/EU approvals recorded (US 1985) but status is "established" |
| NBTXR3 (hafnium oxide nanoparticles) | drug | US/EU approvals recorded (EU 2019) but status is "phase-3" |
| Peginterferon alfa-2b | drug | US/EU approvals recorded (US 2011) but status is "established" |
| Porfimer sodium | drug | US/EU approvals recorded (US 1995) but status is "established" |
| Propranolol (Hemangeol) | drug | US/EU approvals recorded (US 2014) but status is "established" |
| Ravulizumab | drug | US/EU approvals recorded (US 2018) but status is "established" |
| Romiplostim | drug | US/EU approvals recorded (US 2008) but status is "established" |
| Sargramostim | drug | US/EU approvals recorded (US 1991) but status is "established" |
| Streptozocin | drug | US/EU approvals recorded (US 1982) but status is "established" |
| Teniposide | drug | US/EU approvals recorded (US 1992) but status is "established" |
| Entity | Detail | |
|---|---|---|
| ANCHOR | trial | text says randomised 4,459 but enrolled is 4446 |
| CK-301-101 | trial | text says enrolled 109 but enrolled is 272 |
| CONKO-007 | trial | text says enrolled 525 but enrolled is 336 |
| CROSS | trial | text says randomised 368 but enrolled is 366 |
| DESTINY-CRC01 | trial | text says enrolled 78 but enrolled is 86 |
| FoRT | trial | text says randomised 614 but enrolled is 548 |
| HALO 109-301 | trial | text says randomised 494 but enrolled is 492 |
| KEYNOTE-158 | trial | text says enrolled 104 but enrolled is 1609 |
| NeoTRIP (NeoTRIPaPDL1) | trial | text says randomised 280 but enrolled is 278 |
| ROAR (Rare Oncology Agnostic Research) basket: BRAF V600E biliary tract cancer cohort | trial | text says enrolled 43 but enrolled is 206 |
| SWOG 9346 (intermittent androgen deprivation) | trial | text says enrolled 3,040 but enrolled is 1535 |
| TROPHIMMUN | trial | text says enrolled 15 but enrolled is 24 |
| Peginterferon alfa-2b | drug | text mentions approval in 2000 but the earliest recorded approval is 2011; add the missing approvals[] row or correct the year |
| Entity | Detail | |
|---|---|---|
| 5-Aminolevulinic acid (oral, for glioma surgery) | drug | status "approved" but every linked trial is still running (Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302): recruiting); link the pivotal trial or note that the approval was accelerated on earlier data |
| Afamitresgene autoleucel | drug | status "approved" but every linked trial is still running (SPEARHEAD-3 Pediatric Study: recruiting, Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma: active); link the pivotal trial or note that the approval was accelerated on earlier data |
| Alemtuzumab | drug | status "approved" but every linked trial is still running (Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data |
| Allogeneic regulatory T cell immunotherapy with HSPC and T cells-vldq | drug | status "approved" but every linked trial is still running (Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies: active); link the pivotal trial or note that the approval was accelerated on earlier data |
| Amifostine | drug | status "approved" but every linked trial is still running (A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data |
| Aprepitant (and fosaprepitant) | drug | status "approved" but every linked trial is still running (Study With IV NEPA (Fosnetupitant/Palonosetron) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Paediatric Cancer Patients Undergoing Highly Emetogenic Chemotherapy (HEC): recruiting); link the pivotal trial or note that the approval was accelerated on earlier data |
| Asciminib | drug | status "approved" but every linked trial is still running (Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP: recruiting, Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.: recruiting, A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP: active, Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia: recruiting, Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia: active, A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP): active, Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL): recruiting); link the pivotal trial or note that the approval was accelerated on earlier data |
| Belinostat | drug | status "approved" but every linked trial is still running (Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL: recruiting, To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data |
| Benmelstobart | drug | status "approved" but every linked trial is still running (Circulating Tumor DNA Guided Boost Therapy in Early Triple Negative Breast Patients With Residual Disease After Neoadjuvant Therapy: recruiting, The Safety and Efficacy of Benmelstobart Injection in Patients With Advanced Biliary Tract Malignant Tumors: planned, Umbrella Trial of Adjuvant Therapy in Completely Resected High-risk Stage IA-IB NSCLC: Focus on Driver Mutations: planned, A Clinical Study of TQB2450 Combined With Anlotinib in Limited-Stage Small Cell Lung Cancer Patients: planned, A Study of Benmelstobart, Anlotinib, Chemotherapy and Thoracic Radiotherapy for People With Extensive-stage Small Cell Lung Cancer: planned, Clinical Trials of Benmelstobart Injection Combined With Anlotinib Hydrochloride Capsules in the Treatment of Advanced or Unresectable Alveolar Soft Part Sarcoma: recruiting, An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data |
| Bosutinib | drug | status "approved" but every linked trial is still running (TAPUR (Targeted Agent and Profiling Utilization Registry): recruiting, A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP: active); link the pivotal trial or note that the approval was accelerated on earlier data |
| Carfilzomib | drug | status "approved" but every linked trial is still running (A Study of Daratumumab: active, A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With: active, MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other: recruiting, Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refracto: active, A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Rela: recruiting, A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants W: active, A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Tre: active, A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-spe: recruiting, A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory: active, A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Mult: recruiting, Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM): active, A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Darat: recruiting, A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple: active); link the pivotal trial or note that the approval was accelerated on earlier data |
| Cetuximab sarotalocan | drug | status "approved" but every linked trial is still running (A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of : recruiting); link the pivotal trial or note that the approval was accelerated on earlier data |
| clonoSEQ | drug | status "approved" but every linked trial is still running (Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance: recruiting, A Study to Evaluate the Impact of Mosunetuzumab Consolidation for Older Patients With Diffuse Large B-cell Lymphoma (DLBCL) Who Have Detectable Amounts of ctDNA (Circulating Tumor DNA) at the End of Treatment With Pola-R-mini-CHP: recruiting, Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data |
| Decitabine | drug | status "approved" but every linked trial is still running (Phase Ib/II Clinical Study of Adebrelimab in Combination With Decitabine, Albumin-bound Paclitaxel, and Gemcitabine for the First-line Treatment of Metastatic P: recruiting, Exploring Sintilimab + Bevacizumab + Decitabine for Advanced pMMR/MSS Colorectal Cancer (After 2+ Prior Therapies): planned, A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia: active, Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2: active, Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML: recruiting, Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.: active); link the pivotal trial or note that the approval was accelerated on earlier data |
| Disitamab vedotin | drug | status "approved" but every linked trial is still running (Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer: planned, RC48 Combined With Chemotherapy in HER2-Positive Advanced Breast Cancer Patients With Prior TOP1i-ADC Failure: planned, A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent o: recruiting, Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.: recruiting, Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer: recruiting, To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer: recruiting, A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2: active, DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy: recruiting, DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer: recruiting, To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2: recruiting, A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors: active, A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.: recruiting, Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2: active, A Trial of SHR-A2102 With or Without Antitumor Therapy in Advanced Solid Tumors: recruiting, A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer: active, Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer: recruiting, A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data |
| Dordaviprone | drug | status "approved" but every linked trial is still running (ACTION: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data |
| Duvelisib | drug | status "approved" but every linked trial is still running (A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data |
| Eflapegrastim | drug | status "approved" but every linked trial is still running (A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data |
| Elotuzumab | drug | status "approved" but every linked trial is still running (A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Re: recruiting, MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other: recruiting, Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refracto: active, A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortez: active, A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Tre: active); link the pivotal trial or note that the approval was accelerated on earlier data |
| Enasidenib | drug | status "approved" but every linked trial is still running (Beat AML Master Trial: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data |
| Envafolimab | drug | status "approved" but every linked trial is still running (A Clinical Study to Evaluate the Efficacy and Safety of Envafolimab Combined With Cetuxima-βand mFOLFOX6 in Patients With MSS, RAS/BRAF Wild-Type Metastatic Col: planned, Organ Preservation Following Enverolimab-based Total Neoadjuvant Therapy for Locally Advanced Very Low Rectal Cancer: planned, Preoperative Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Rectal Adenocarcinoma: recruiting, Multicenter Phase 2 Study of Envafolimab in Biliary Tract Cancers: planned, Envafolimab With Chemotherapy and Simvastatin in Advanced Biliary Tract Cancer: planned, Gemcitabine-Cisplatin Plus Envafolimab in Resectable Biliary Tract Malignancies: planned, A Phase II Exploratory Study of Sacituzumab Tirumotecan Combined With Envafolimab for TROP2-Positive Advanced Biliary Tract Cancers Previously Treated With First-Line Immunotherapy Combined With Chemotherapy.: planned, Hepatic Arterial Infusion Chemotherapy Plus Envafolimab and Lenvatinib for First-Line Unresectable Advanced Biliary Tract Cancer: recruiting, Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer: recruiting, Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors: recruiting, Phase III Study of Envafolimab Versus Placebo Plus Chemotherapy in Resectable Stage III NSCLC: recruiting, ENVAFOLIMAB Single-agent Treatment in Patients With Advanced Solid Tumors: recruiting, Programmed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTC: active, KN035 for dMMR/MSI-H Advanced Solid Tumors: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data |
| Fedratinib | drug | status "approved" but every linked trial is still running (A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis): active); link the pivotal trial or note that the approval was accelerated on earlier data |
| Flotufolastat F-18 | drug | status "approved" but every linked trial is still running (Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance: recruiting, Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT: recruiting, PET Scan Study to Detect Prostate Cancer in Patients with Early PSA Recurrence: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data |
| Fludeoxyglucose F-18 (FDG) | drug | status "approved" but every linked trial is still running (AHOD2131 (COG / NCTN): recruiting, Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer: active, Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer: recruiting, A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations: recruiting, Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer: recruiting, Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted Therapy: active); link the pivotal trial or note that the approval was accelerated on earlier data |
| Fulzerasib | drug | status "approved" but every linked trial is still running (IBI351 Plus Cetuximab β in Untreated Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation: recruiting, Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC: recruiting, A Trial of HRS-7058 in Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment: planned, Neoadjuvant Treatment of Fulzerasib Plus Cetuximab N01 in KRAS G12C Mutated Locally Advanced Colorectal Cancer With or Without Resectable Metastases: recruiting, A Multicenter, Single-arm Phase II Study to Evaluate the Efficacy and Safety of Fulzerasib (IBI351) in Combination With Ivonescimab (AK-112) in First-line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer Patients With KRAS G12C Mutation: planned); link the pivotal trial or note that the approval was accelerated on earlier data |
| Garsorasib | drug | status "approved" but every linked trial is still running (A Trial of HRS-7058 in Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment: planned, D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standar: recruiting, Study to Evaluate D-1553 in Subjects With Solid Tumors: active, Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors: active); link the pivotal trial or note that the approval was accelerated on earlier data |
| Gedatolisib | drug | status "approved" but every linked trial is still running (Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer: recruiting, Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1): active, Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2): recruiting); link the pivotal trial or note that the approval was accelerated on earlier data |
| Glecirasib | drug | status "approved" but every linked trial is still running (A Study of BL-B01D1 Combined With Glecirasib in Patients With KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer: planned, A Trial of HRS-7058 in Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment: planned, JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation: active, Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation: recruiting, A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Glecirasib: recruiting, A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1: recruiting, A Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China: active, A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.: recruiting, JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data |
| Glumetinib | drug | status "approved" but every linked trial is still running (A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in N: recruiting, Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors: recruiting, Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data |
| Golidocitinib | drug | status "approved" but every linked trial is still running (Golidocitinib in Combination With Sintilimab for PD-L1 Selected Treatment Locally Advanced or Metastatic Non-Small Cell Lung Cancer(NSCLC): planned, Golidocitinib With PD-1 Inhibitors as Maintenance Treatment for Previously Untreated ES-SCLC: recruiting, A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19): recruiting, Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3): recruiting); link the pivotal trial or note that the approval was accelerated on earlier data |
| Entity | Detail | |
|---|---|---|
| Amrubicin | drug | approved only outside US/EU (JP 2002); status "established" describes the global stage |
| Entity | Detail | |
|---|---|---|
| 131I-MIBG (iobenguane I-131) therapy | drug | text mentions approval but status is "established" |
| Alitretinoin | drug | text mentions approval but status is "established" |
| Altretamine | drug | text mentions approval but status is "established" |
| Aminoglutethimide | drug | text mentions approval but status is "historic" |
| Amsacrine | drug | text mentions approval but status is "established" |
| CAM2029 (octreotide subcutaneous depot) | drug | text mentions approval but status is "phase-3" |
| Choline C-11 | drug | text mentions approval but status is "established" |
| Cinacalcet | drug | text mentions approval but status is "established" |
| Dronabinol | drug | text mentions approval but status is "established" |
| Eltrombopag | drug | text mentions approval but status is "established" |
| Estramustine | drug | text mentions approval but status is "established" |
| Ethiodized oil | drug | text mentions approval but status is "established" |
| Fenbendazole (veterinary anthelmintic) | drug | text mentions approval but status is "preclinical" |
| Floxuridine | drug | text mentions approval but status is "established" |
| Fostamatinib | drug | text mentions approval but status is "established" |
| Ivermectin | drug | text mentions approval but status is "phase-2" |
| Methoxsalen (extracorporeal photopheresis) | drug | text mentions approval but status is "established" |
| Methyl aminolevulinate | drug | text mentions approval but status is "established" |
| Metyrapone | drug | text mentions approval but status is "established" |
| Peginterferon alfa-2b | drug | text mentions approval but status is "established" |
| Pipobroman | drug | text mentions approval but status is "historic" |
| Plicamycin | drug | text mentions approval but status is "historic" |
| Propranolol (Hemangeol) | drug | text mentions approval but status is "established" |
| Raltitrexed | drug | text mentions approval but status is "established" |
| Romiplostim | drug | text mentions approval but status is "established" |
| Sargramostim | drug | text mentions approval but status is "established" |
| Streptozocin | drug | text mentions approval but status is "established" |
| Teniposide | drug | text mentions approval but status is "established" |
| Uracil mustard | drug | text mentions approval but status is "historic" |
Rule one is cite it. Records with no external source at all, records whose text carries a percentage, hazard ratio, duration or price with no link behind it, and structured trial outcomes without a source.
| Entity | Detail | |
|---|---|---|
| AHL2011 | trial | 1 of 2 structured outcomes carry numbers without a source: Grade 3 to 4 anaemia |
| Alliance N0574 (NCCTG N0574) | trial | 1 of 1 structured outcome carry numbers without a source: Cognitive deterioration at 3 months |
| Alliance/CALGB 50303 | trial | 2 of 3 structured outcomes carry numbers without a source: Overall survival; Febrile neutropenia |
| ASCENT-03 | trial | 1 of 3 structured outcomes carry numbers without a source: Objective response rate |
| BL-B01D1-307 | trial | 1 of 3 structured outcomes carry numbers without a source: Confirmed objective response rate (BICR) |
| Bonner trial (cetuximab plus radiotherapy) | trial | 1 of 1 structured outcome carry numbers without a source: Locoregional control (primary) and overall survival |
| CALGB 9343 | trial | 1 of 1 structured outcome carry numbers without a source: Locoregional recurrence at 10 years |
| CAO/ARO/AIO-94 (German Rectal Cancer Study) | trial | 1 of 1 structured outcome carry numbers without a source: Local recurrence at 5 years |
| CAPTAIN-1st | trial | 1 of 1 structured outcome carry numbers without a source: Progression-free survival |
| CHHiP | trial | 1 of 4 structured outcomes carry numbers without a source: Biochemical or clinical failure-free survival at 5 years |
| CYTO-PV | trial | 1 of 1 structured outcome carry numbers without a source: Cardiovascular death or major thrombosis |
| DAHANCA 5 | trial | 1 of 1 structured outcome carry numbers without a source: Locoregional control at 5 years |
| DBCG 82b and 82c | trial | 1 of 1 structured outcome carry numbers without a source: Overall survival at 10 years (82b) |
| ECOG-ACRIN E3311 | trial | 1 of 1 structured outcome carry numbers without a source: Progression-free survival at 2 years |
| ELARA | trial | 1 of 2 structured outcomes carry numbers without a source: Objective response rate |
| EMERALD-1 | trial | 2 of 2 structured outcomes carry numbers without a source: Progression-free survival; Overall survival |
| ENRICH | trial | 2 of 3 structured outcomes carry numbers without a source: Progression-free survival, R-CHOP stratum; Progression-free survival, bendamustine-rituximab stratum |
| EORTC 08993 (Slotman): prophylactic cranial irradiation in extensive-stage small-cell lung cancer | trial | 1 of 1 structured outcome carry numbers without a source: Symptomatic brain metastases within 1 year |
| EORTC 22922/10925 | trial | 1 of 1 structured outcome carry numbers without a source: Overall survival at 10 years |
| EORTC/LYSA/FIL H10 | trial | 2 of 3 structured outcomes carry numbers without a source: Progression-free survival at 5 years, scan-negative favourable group; Progression-free survival at 5 years, scan-negative unfavourable group |
| EPCORE DLBCL-1 | trial | 1 of 2 structured outcomes carry numbers without a source: Progression-free survival |
| EV-303 / KEYNOTE-905 | trial | 2 of 3 structured outcomes carry numbers without a source: Overall survival; Pathologic complete response |
| evERA | trial | 1 of 2 structured outcomes carry numbers without a source: Progression-free survival (ESR1-mutant) |
| FAST-Forward | trial | 1 of 1 structured outcome carry numbers without a source: Ipsilateral breast tumour relapse at 5 years |
| GHSG HD16 | trial | 1 of 2 structured outcomes carry numbers without a source: Overall survival at 5 years |
| GHSG HD18 | trial | 2 of 3 structured outcomes carry numbers without a source: Progression-free survival at 5 years, scan-positive cohort; Severe infections, scan-negative cohort |
| HYPO-RT-PC | trial | 1 of 3 structured outcomes carry numbers without a source: Failure-free survival at 5 years |
| iMMagine-1 | trial | 1 of 1 structured outcome carry numbers without a source: Objective response rate |
| IMPORT LOW | trial | 1 of 1 structured outcome carry numbers without a source: Local relapse at 5 years |
| INT-0116 (Macdonald trial) | trial | 1 of 1 structured outcome carry numbers without a source: Median overall survival |
| Entity | Detail | |
|---|---|---|
| AML with myelodysplasia-related gene mutations (AML-MR) | term | 1 number in the text (9.6 months) but no link, Wikipedia page or registry id |
| B-ALL risk groups (NCI criteria, ETV6::RUNX1, hyperdiploidy, hypodiploidy, iAMP21, IKZF1, CNS status) | term | 5 numbers in the text (0.01 percent, 95 percent, 2 percent, 15 percent) but no link, Wikipedia page or registry id |
| BCR::ABL1 kinase domain mutations (T315I and others) | term | 2 numbers in the text (3 percent, 20 percent) but no link, Wikipedia page or registry id |
| BRCA reversion mutations | term | 1 number in the text (40 percent) but no link, Wikipedia page or registry id |
| CLL-IPI (chronic lymphocytic leukaemia prognostic index) | term | 2 numbers in the text (23 percent, 98 percent) but no link, Wikipedia page or registry id |
| Decide who is screened for lung cancer by individual risk, not by pack-years | idea | 2 numbers in the text (31 percent, 17 percent) but no link, Wikipedia page or registry id |
| DIPSS, DIPSS-plus and MIPSS70 (myelofibrosis risk scores) | term | 1 number in the text (1 percent) but no link, Wikipedia page or registry id |
| FOXO1 fusion status and IRS group (rhabdomyosarcoma) | term | 2 numbers in the text (60 percent, 20 percent) but no link, Wikipedia page or registry id |
| GIST risk stratification (mitotic count, size, site; Miettinen and modified NIH criteria) | term | 3 numbers in the text (2 percent, 90 percent, 82 percent) but no link, Wikipedia page or registry id |
| Gracell Biotechnologies | company | 1 number in the text (1.2 billion) but no link, Wikipedia page or registry id |
| Hervé Dombret | person | 1 number in the text (30 percent) but no link, Wikipedia page or registry id |
| Histological response to induction chemotherapy (osteosarcoma and Ewing sarcoma) | term | 7 numbers in the text (90 percent, 50 percent, 75 percent, 57 percent) but no link, Wikipedia page or registry id |
| Inge M. van der Sluis | person | 1 number in the text (80 percent) but no link, Wikipedia page or registry id |
| Make resistance a diagnosis: sequence at every progression and choose the next line from what the tumour became | idea | 1 number in the text (14 percent) but no link, Wikipedia page or registry id |
| MET exon 14 skipping mutation | term | 5 numbers in the text (3 percent, 20 percent, 4 percent, 30 percent) but no link, Wikipedia page or registry id |
| MIBG Curie and SIOPEN scores | term | 1 number in the text (10 percent) but no link, Wikipedia page or registry id |
| MIPI (Mantle Cell Lymphoma International Prognostic Index) | term | 4 numbers in the text (30 percent, 51 months, 29 months) but no link, Wikipedia page or registry id |
| MLH1 promoter methylation (sporadic versus Lynch mismatch repair loss) | term | 2 numbers in the text (70 percent, 90 percent) but no link, Wikipedia page or registry id |
| MPN driver mutations (JAK2 V617F, CALR, MPL) and allele burden | term | 4 numbers in the text (95 percent, 3 percent, 60 percent, 50 percent) but no link, Wikipedia page or registry id |
| Patidegib | drug | 1 number in the text (2 percent) but no link, Wikipedia page or registry id |
| Ph-like (BCR::ABL1-like) acute lymphoblastic leukaemia | term | 3 numbers in the text (15 percent, 30 percent, 20 percent) but no link, Wikipedia page or registry id |
| PSA kinetics: PSA doubling time and PSA density | term | 1 number in the text (50 percent) but no link, Wikipedia page or registry id |
| Publish a per-lesion miss rate for every prostate MRI service before it is allowed to guide focal treatment | idea | 6 numbers in the text (93 percent, 41 percent, 45 percent, 65 percent) but no link, Wikipedia page or registry id |
| Randomise the order of treatment, not only the drugs: a strategy platform for metastatic prostate cancer | idea | 4 numbers in the text (hazard ratio of 0.44, 8.6 months, 3.8 months, 10.9 months) but no link, Wikipedia page or registry id |
| SDH deficiency (SDHB immunohistochemistry loss) | term | 2 numbers in the text (7 percent, 40 percent) but no link, Wikipedia page or registry id |
| Segmental chromosomal aberrations and ploidy (neuroblastoma) | term | 1 number in the text (40 percent) but no link, Wikipedia page or registry id |
| Small-cell lung cancer transcription-factor subtypes (SCLC-A, SCLC-N, SCLC-P, SCLC-I) and SLFN11 | term | 1 number in the text (15 percent) but no link, Wikipedia page or registry id |
| Sokal and ELTS risk scores (chronic myeloid leukaemia) | term | 4 numbers in the text (12 percent, 10 percent, 1 percent, 0.1 percent) but no link, Wikipedia page or registry id |
| SS18::SSX fusion (synovial sarcoma) | term | 4 numbers in the text (95 percent, 100 percent, 70 percent, 80 percent) but no link, Wikipedia page or registry id |
| Take high-dose testosterone to phase 3, with progression-free survival through the second line as the primary endpoint | idea | 8 numbers in the text (30 percent, 50 percent, 52 percent, hazard ratio 0.44) but no link, Wikipedia page or registry id |
| Entity | Detail | |
|---|---|---|
| 1746 in oncology | year | no external link or Wikipedia reference |
| 1775 in oncology | year | no external link or Wikipedia reference |
| 1777 in oncology | year | no external link or Wikipedia reference |
| 1806 in oncology | year | no external link or Wikipedia reference |
| 1809 in oncology | year | no external link or Wikipedia reference |
| 1812 in oncology | year | no external link or Wikipedia reference |
| 1814 in oncology | year | no external link or Wikipedia reference |
| 1823 in oncology | year | no external link or Wikipedia reference |
| 1832 in oncology | year | no external link or Wikipedia reference |
| 1834 in oncology | year | no external link or Wikipedia reference |
| 1838 in oncology | year | no external link or Wikipedia reference |
| 1840 in oncology | year | no external link or Wikipedia reference |
| 1842 in oncology | year | no external link or Wikipedia reference |
| 1844 in oncology | year | no external link or Wikipedia reference |
| 1845 in oncology | year | no external link or Wikipedia reference |
| 1855 in oncology | year | no external link or Wikipedia reference |
| 1857 in oncology | year | no external link or Wikipedia reference |
| 1859 in oncology | year | no external link or Wikipedia reference |
| 1869 in oncology | year | no external link or Wikipedia reference |
| 1870 in oncology | year | no external link or Wikipedia reference |
| 1872 in oncology | year | no external link or Wikipedia reference |
| 1873 in oncology | year | no external link or Wikipedia reference |
| 1874 in oncology | year | no external link or Wikipedia reference |
| 1875 in oncology | year | no external link or Wikipedia reference |
| 1878 in oncology | year | no external link or Wikipedia reference |
| 1879 in oncology | year | no external link or Wikipedia reference |
| 1880 in oncology | year | no external link or Wikipedia reference |
| 1881 in oncology | year | no external link or Wikipedia reference |
| 1882 in oncology | year | no external link or Wikipedia reference |
| 1883 in oncology | year | no external link or Wikipedia reference |
Parallel editing leaves seams: records nothing links to, the same name in two kinds, names two characters apart inside a kind, two products with one development code, and spike duplicates whose values diverge (the first copy wins silently). Each row says what a merge would look like.
| Entity | Detail | |
|---|---|---|
| 1p/19q codeletion | term | same normalised name as 1p19q-codeletion-readout (biomarker) |
| 1p/19q codeletion | biomarker | same normalised name as 1p19q-codeletion (term) |
| A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors | trial | same normalised name as nct06581419 (trial) |
| A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors | trial | same normalised name as nct06223841 (trial) |
| Acute myeloid leukaemia | cancer | same normalised name as aml-signalling (pathway) |
| Acute myeloid leukaemia (KEGG map) | pathway | same normalised name as aml (cancer) |
| Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC) | trial | same normalised name as nct07480213 (trial) |
| Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC) | trial | same normalised name as nct07744256 (trial) |
| Adaptive therapy | paper | same normalised name as adaptive-therapy-dynamics (technology) |
| Adaptive therapy (evolution-based dosing) | technology | same normalised name as paper-gatenby-cancer-res (paper) |
| Adjuvant Vinorelbine Plus Cisplatin (NP) Versus NP Plus Endostar in Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer | trial | same normalised name as nct01124253 (trial) |
| Adjuvant Vinorelbine Plus Cisplatin(NP) Versus NP Plus Endostar in Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer(NSCLC) | trial | same normalised name as nct00576914 (trial) |
| Alex's Lemonade Stand Foundation | institution | same normalised name as alexs-lemonade-stand (collection) |
| Alex's Lemonade Stand Foundation (ALSF) | collection | same normalised name as alsf (institution) |
| Angiosarcoma | cancer | same normalised name as paper-young-angiosarcoma-review-lancet-oncol-2010 (paper) |
| Angiosarcoma (review) | paper | same normalised name as angiosarcoma (cancer) |
| AR-V7 splice variant | term | same normalised name as ar-v7-splice-variant (biomarker) |
| AR-V7 splice variant | biomarker | same normalised name as ar-v7 (term) |
| Autologous stem cell transplant (ASCT) | term | same normalised name as autologous-stem-cell-transplant (technology) |
| Autologous stem cell transplant (high-dose therapy) | technology | same normalised name as autologous-transplant (term) |
| Basal cell carcinoma | cancer | same normalised name as basal-cell-carcinoma-signalling (pathway) |
| Basal cell carcinoma (KEGG map) | pathway | same normalised name as basal-cell-carcinoma (cancer) |
| BCR::ABL1 (Philadelphia chromosome) | target | same normalised name as bcr-abl1-signalling (pathway) |
| BCR::ABL1 (Philadelphia chromosome) | pathway | same normalised name as bcr-abl (target) |
| Bevacizumab | drug | same normalised name as bevacizumab-glioma (drug) |
| Bevacizumab (glioblastoma use) | drug | same normalised name as bevacizumab (drug) |
| Biliary tract cancer (all types) | cancer | same normalised name as cholangiocarcinoma (cancer) |
| Biliary tract cancer (cholangiocarcinoma) | cancer | same normalised name as biliary-tract-cancer (cancer) |
| Brachytherapy | technology | same normalised name as brachytherapy-term (term) |
| Brachytherapy (internal radiotherapy) | term | same normalised name as brachytherapy (technology) |
| Entity | Detail | |
|---|---|---|
| ARHGEF10 | target | "ARHGEF10" and "ARHGEF10L" (arhgef10l) differ by at most two characters; if they are one thing, keep arhgef10, move "ARHGEF10L" into its aka and repoint links |
| CARGO Therapeutics | company | "CARGO Therapeutics" and "CARTx Therapeutics" (cartx-therapeutics) differ by at most two characters; if they are one thing, keep cargo-therapeutics, move "CARTx Therapeutics" into its aka and repoint links |
| CheckMate 9DW | trial | "CheckMate 9DW" and "CheckMate 9ER" (checkmate-9er) differ by at most two characters; if they are one thing, keep checkmate-9dw, move "CheckMate 9ER" into its aka and repoint links |
| CheckMate 9DW | trial | "CheckMate 9DW" and "CheckMate 9LA" (checkmate-9la) differ by at most two characters; if they are one thing, keep checkmate-9dw, move "CheckMate 9LA" into its aka and repoint links |
| CheckMate 9ER | trial | "CheckMate 9ER" and "CheckMate 9LA" (checkmate-9la) differ by at most two characters; if they are one thing, keep checkmate-9er, move "CheckMate 9LA" into its aka and repoint links |
| Corbus Pharmaceuticals | company | "Corbus Pharmaceuticals" and "Corvus Pharmaceuticals" (corvus-pharmaceuticals) differ by at most two characters; if they are one thing, keep corbus-pharmaceuticals, move "Corvus Pharmaceuticals" into its aka and repoint links |
| Dabrafenib plus trametinib in previously treated BRAF V600E-mutant metastatic non-small-cell lung cancer | paper | "Dabrafenib plus trametinib in previously treated BRAF V600E-mutant metastatic non-small-cell lung cancer" and "Dabrafenib plus trametinib in previously untreated BRAF V600E-mutant metastatic non-small-cell lung cancer" (paper-planchard-dabrafenib-trametinib-first-line-lancet-oncol-2017) differ by at most two characters; if they are one thing, keep paper-planchard-dabrafenib-trametinib-braf-nsclc-lancet-oncol-2016, move "Dabrafenib plus trametinib in previously untreated BRAF V600E-mutant metastatic non-small-cell lung cancer" into its aka and repoint links |
| Dysphagia (difficulty swallowing) | term | "Dysphagia (difficulty swallowing)" and "Dysplasia (pre-cancerous change)" (dysplasia) differ by at most two characters; if they are one thing, keep dysphagia, move "Dysplasia (pre-cancerous change)" into its aka and repoint links |
| Feng Zhang | person | "Feng Zhang" and "Feng Wang" (wang-feng-sysucc) differ by at most two characters; if they are one thing, keep feng-zhang, move "Feng Wang" into its aka and repoint links |
| FLT3-ITD (internal tandem duplication) | biomarker | "FLT3-ITD (internal tandem duplication)" and "FLT3-TKD (D835 and I836 tyrosine kinase domain mutations)" (flt3-tkd) differ by at most two characters; if they are one thing, keep flt3-itd, move "FLT3-TKD (D835 and I836 tyrosine kinase domain mutations)" into its aka and repoint links |
| HSP90AA1 | target | "HSP90AA1" and "HSP90AB1" (hsp90ab1) differ by at most two characters; if they are one thing, keep hsp90aa1, move "HSP90AB1" into its aka and repoint links |
| Instituto Nacional de Câncer (INCA) | institution | "Instituto Nacional de Câncer (INCA)" and "Instituto Nacional del Cáncer (Uruguay)" (inca-uruguay) differ by at most two characters; if they are one thing, keep inca-brazil, move "Instituto Nacional del Cáncer (Uruguay)" into its aka and repoint links |
| Instituto Nacional del Cáncer (Argentina) | institution | "Instituto Nacional del Cáncer (Argentina)" and "Instituto Nacional de Câncer (INCA)" (inca-brazil) differ by at most two characters; if they are one thing, keep inc-argentina, move "Instituto Nacional de Câncer (INCA)" into its aka and repoint links |
| Instituto Nacional del Cáncer (Chile) | institution | "Instituto Nacional del Cáncer (Chile)" and "Instituto Nacional de Câncer (INCA)" (inca-brazil) differ by at most two characters; if they are one thing, keep inc-chile, move "Instituto Nacional de Câncer (INCA)" into its aka and repoint links |
| InterAACT | trial | "InterAACT" and "INTERLACE" (interlace) differ by at most two characters; if they are one thing, keep interaact, move "INTERLACE" into its aka and repoint links |
| KRAS G12C | biomarker | "KRAS G12C" and "KRAS G12D (and other non-G12C KRAS mutations)" (kras-g12d) differ by at most two characters; if they are one thing, keep kras-g12c, move "KRAS G12D (and other non-G12C KRAS mutations)" into its aka and repoint links |
| MAJIC-ET | trial | "MAJIC-ET" and "MAJIC-PV" (majic-pv) differ by at most two characters; if they are one thing, keep majic-et, move "MAJIC-PV" into its aka and repoint links |
| NAVIGATE | trial | "NAVIGATE" and "NAVIGATOR" (navigator) differ by at most two characters; if they are one thing, keep navigate, move "NAVIGATOR" into its aka and repoint links |
| Neoplasia | journal | "Neoplasia" and "Neoplasma" (neoplasma) differ by at most two characters; if they are one thing, keep neoplasia, move "Neoplasma" into its aka and repoint links |
| Newly diagnosed multiple myeloma, transplant-eligible | cancer | "Newly diagnosed multiple myeloma, transplant-eligible" and "Newly diagnosed multiple myeloma, transplant-ineligible" (myeloma-transplant-ineligible) differ by at most two characters; if they are one thing, keep myeloma-transplant-eligible, move "Newly diagnosed multiple myeloma, transplant-ineligible" into its aka and repoint links |
| Nicolas Penel | person | "Nicolas Penel" and "Nicolas Revel" (nicolas-revel) differ by at most two characters; if they are one thing, keep nicolas-penel, move "Nicolas Revel" into its aka and repoint links |
| PD-L1 CPS (combined positive score) | biomarker | "PD-L1 CPS (combined positive score)" and "PD-L1 TPS (tumour proportion score)" (pd-l1-tps) differ by at most two characters; if they are one thing, keep pd-l1-cps, move "PD-L1 TPS (tumour proportion score)" into its aka and repoint links |
| PD-L1 IC score (immune-cell score, SP142) | biomarker | "PD-L1 IC score (immune-cell score, SP142)" and "PD-L1 TC score (tumour-cell score, SP263 and 28-8)" (pd-l1-tc-score) differ by at most two characters; if they are one thing, keep pd-l1-ic-score, move "PD-L1 TC score (tumour-cell score, SP263 and 28-8)" into its aka and repoint links |
| RADICALS-HD | trial | "RADICALS-HD" and "RADICALS-RT" (radicals-rt) differ by at most two characters; if they are one thing, keep radicals-hd, move "RADICALS-RT" into its aka and repoint links |
| RELEVANCE | trial | "RELEVANCE" and "RELIANCE" (reliance) differ by at most two characters; if they are one thing, keep relevance, move "RELIANCE" into its aka and repoint links |
| Tae Won Kim | person | "Tae Won Kim" and "Tae-You Kim" (kim-tae-you) differ by at most two characters; if they are one thing, keep kim-tae-won, move "Tae-You Kim" into its aka and repoint links |
| TGRX-326 Chinese Phase II for Advanced Non-small Cell Lung Cancer (NSCLC) | trial | "TGRX-326 Chinese Phase II for Advanced Non-small Cell Lung Cancer (NSCLC)" and "TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC)" (nsclc-3) differ by at most two characters; if they are one thing, keep nct05955391, move "TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC)" into its aka and repoint links |
| Entity | Detail | |
|---|---|---|
| Breast reconstruction | term | defined in the breast-cancer spikes with different values; the first wins and hides the rest: tldr: "Rebuilding the shape of a breast after a mastectomy, eith..." vs "Surgery to make a breast shape after a mastectomy, using ..."; summary: "There are two families of technique. Implant-based recons..." vs "NICE NG101 says to offer breast reconstruction to people ..." |
| Curettage and cautery | term | defined in the skin-cancer spikes with different values; the first wins and hides the rest: tldr: "Scraping a small, low-risk skin cancer away with a spoon-..." vs "The tumour is scraped out with a sharp spoon-shaped instr..."; summary: "The British Association of Dermatologists describes curet..." vs "Curettage with or without electrodesiccation is the faste..." |
| EGFR mutation and resistance of non-small-cell lung cancer to gefitinib | paper | defined in the lung-cancer and nsclc spikes with different values; the first wins and hides the rest: tldr: "One patient, two years in complete remission on gefitinib..." vs "One patient whose lung cancer had disappeared for two yea..."; summary: "Kobayashi, Boggon, Dayaram and colleagues at Beth Israel ..." vs "A patient with EGFR-mutant, gefitinib-responsive advanced..."; whatItMeans: "Resistance to a targeted drug usually has a cause you can..." vs "It established that acquired resistance to a targeted dru..." |
| Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer | paper | defined in the lung-cancer and nsclc spikes with different values; the first wins and hides the rest: tldr: "A small inversion on chromosome 2 fuses two genes and mak..." vs "A small inversion on chromosome 2 was found to weld two g..."; summary: "Soda, Choi, Enomoto and colleagues, with Mano as senior a..." vs "A small inversion within chromosome 2p was shown to form ..."; whatItMeans: "The second driver in lung cancer, and the one that proved..." vs "It created the second targetable class in lung cancer and..." |
| Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data | paper | defined in the lung-cancer and nsclc spikes with different values; the first wins and hides the rest: tldr: "Small-cell lung cancer, treated as one disease for fifty ..." vs "Small-cell lung cancer has been treated as a single disea..."; summary: "Rudin, Poirier, Byers, Dive and eighteen colleagues propo..." vs "Evidence from primary human tumours, patient-derived xeno..."; whatItMeans: "The organising framework for every small-cell lung cancer..." vs "It reorganised a disease that had no molecular classifica..." |
| SEQUOIA | trial | defined in the cll and pancreatic spikes with different values; the first wins and hides the rest: name: "SEQUOIA" vs "SEQUOIA (pancreatic cancer)"; nct: "NCT03336333" vs "NCT02923921"; status: "positive" vs "negative"; yearReported: "2022" vs "2021"; sponsor: "BeOne (BeiGene)" vs "Eli Lilly (ARMO BioSciences)"; enrolled: "590" vs "567"; setting: "Previously untreated CLL/SLL unsuitable for FCR: zanubrut..." vs "Metastatic pancreatic ductal adenocarcinoma progressing a..."; tldr: "Zanubrutinib beat chemoimmunotherapy in untreated CLL and..." vs "SEQUOIA added the immune cytokine pegilodecakin to second..."; summary: "SEQUOIA, trial NCT03336333 sponsored by BeOne, formerly B..." vs "SEQUOIA randomised 567 patients between March 2017 and Se..."; result: "PFS HR 0.42 vs BR; 5-year PFS 72.2% in del(17p)." vs "Median overall survival 5.8 months with pegilodecakin plu..." |
| Entity | Detail | |
|---|---|---|
| 7+3 induction chemotherapy | term | "cytarabine anthracycline" is also Cytarabine + anthracycline ('7+3') (cytarabine-7-3, drug); cross-link them with `related` or merge if they describe one thing |
| 7+3 induction chemotherapy | term | "cpx 351" is also CPX-351 (liposomal daunorubicin-cytarabine) (cpx-351, drug); cross-link them with `related` or merge if they describe one thing |
| A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications | paper | "lymphgen" is also Cell of origin (GCB vs ABC) (cell-of-origin, term), LymphGen and the genetic clusters of large B-cell lymphoma (lymphoma-bio-lymphgen, term); cross-link them with `related` or merge if they describe one thing |
| A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After NAC in TNBC | trial | "apollo" is also DCLRE1B (dclre1b, target); cross-link them with `related` or merge if they describe one thing |
| A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC | trial | "titan" is also TITAN (whole-slide multimodal model) (titan, technology); cross-link them with `related` or merge if they describe one thing |
| A Study of NanO2™ Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBM | trial | "restore" is also RESTORE: bipolar androgen therapy after progression on enzalutamide in metastatic castration-resistant prostate cancer (paper-teply-restore-bipolar-androgen-therapy-lancet-oncol-2018, paper); cross-link them with `related` or merge if they describe one thing |
| Adenocarcinoma | term | "ductal adenocarcinoma" is also Ductal adenocarcinoma of the prostate (prostate-ductal-adenocarcinoma, cancer); cross-link them with `related` or merge if they describe one thing |
| Adenocarcinoma | term | "adenocarcinoma" is also Adenocarcinoma of the urethra (including clear cell adenocarcinoma) (urethral-adenocarcinoma, cancer), Adenocarcinoma of the lung (lung-adenocarcinoma, cancer); cross-link them with `related` or merge if they describe one thing |
| Adenocarcinoma | term | "invasive lobular carcinoma" is also Invasive lobular carcinoma of the breast (invasive-lobular-carcinoma, cancer); cross-link them with `related` or merge if they describe one thing |
| Adenocarcinoma of the lung | cancer | "adenocarcinoma" is also Adenocarcinoma (adenocarcinoma, term); cross-link them with `related` or merge if they describe one thing |
| Adenocarcinoma of the urethra (including clear cell adenocarcinoma) | cancer | "adenocarcinoma" is also Adenocarcinoma (adenocarcinoma, term); cross-link them with `related` or merge if they describe one thing |
| Adult T-cell leukaemia/lymphoma | cancer | "atll" is also HTLV-1, Tax and HBZ in adult T-cell leukaemia/lymphoma (lymphoma-bio-htlv1, term); cross-link them with `related` or merge if they describe one thing |
| AFFIRM | trial | "affirm" is also AFFIRM: increased survival with enzalutamide in prostate cancer after chemotherapy (paper-scher-affirm-enzalutamide-nejm-2012, paper); cross-link them with `related` or merge if they describe one thing |
| AFFIRM: increased survival with enzalutamide in prostate cancer after chemotherapy | paper | "affirm" is also AFFIRM (affirm, trial); cross-link them with `related` or merge if they describe one thing |
| After ruxolitinib: belumosudil, axatilimab and ibrutinib in chronic GvHD | technology | "rockstar" is also ROCKstar (rockstar, trial); cross-link them with `related` or merge if they describe one thing |
| Agência Nacional de Vigilância Sanitária | institution | "anvisa" is also Regulators beyond the FDA (EMA/CHMP, MHRA, PMDA, NMPA, TGA) (regulatory-agencies, term); cross-link them with `related` or merge if they describe one thing |
| ALK kinase-domain resistance mutation (G1202R and the rest) | biomarker | "g1202r" is also On-target resistance mutations (gatekeeper, solvent-front, compound) (gatekeeper-mutation, term); cross-link them with `related` or merge if they describe one thing |
| Allogeneic stem cell transplant (allo-SCT) | term | "allogeneic stem cell transplantation" is also Allogeneic stem cell transplantation (allogeneic-hsct, technology); cross-link them with `related` or merge if they describe one thing |
| Allogeneic stem cell transplant (allo-SCT) | term | "post transplant cyclophosphamide" is also Preventing graft-versus-host disease, and what prevention costs (gvhd-prophylaxis, technology); cross-link them with `related` or merge if they describe one thing |
| Allogeneic stem cell transplantation | technology | "allogeneic stem cell transplantation" is also Allogeneic stem cell transplant (allo-SCT) (allogeneic-transplant, term); cross-link them with `related` or merge if they describe one thing |
| An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS | trial | "atlas" is also Atlas (Aignostics, Mayo Clinic, Charité) (atlas-aignostics, technology); cross-link them with `related` or merge if they describe one thing |
| Anaemia | term | "erythropoiesis stimulating agent" is also Epoetin alfa (epoetin-alfa, drug); cross-link them with `related` or merge if they describe one thing |
| Androgen receptor pathway inhibitor (ARPI) | term | "ar v7" is also AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer (paper-antonarakis-ar-v7-resistance-nejm-2014, paper), AR-V7 splice variant (ar-v7-splice-variant, biomarker); cross-link them with `related` or merge if they describe one thing |
| Angiosarcoma (review) | paper | "angiosarcoma" is also Vascular tumours (angiosarcoma, epithelioid haemangioendothelioma, kaposiform haemangioendothelioma) (vascular-tumours, cancer), Angiosarcoma (angiosarcoma, cancer); cross-link them with `related` or merge if they describe one thing |
| AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer | paper | "ar v7" is also Androgen receptor pathway inhibitor (ARPI) (arpi, term), AR-V7 splice variant (ar-v7-splice-variant, biomarker); cross-link them with `related` or merge if they describe one thing |
| AR-V7 splice variant | biomarker | "ar v7" is also AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer (paper-antonarakis-ar-v7-resistance-nejm-2014, paper), Androgen receptor pathway inhibitor (ARPI) (arpi, term); cross-link them with `related` or merge if they describe one thing |
| ASCL1 | target | "ascl1" is also Small-cell lung cancer transcription-factor subtypes (SCLC-A, SCLC-N, SCLC-P, SCLC-I) and SLFN11 (sclc-molecular-subtypes, term); cross-link them with `related` or merge if they describe one thing |
| Atlas (Aignostics, Mayo Clinic, Charité) | technology | "atlas" is also An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS (nct02531516, trial); cross-link them with `related` or merge if they describe one thing |
| Autologous stem cell transplant (ASCT) | term | "autologous stem cell transplant" is also Autologous stem cell transplant (high-dose therapy) (autologous-stem-cell-transplant, technology); cross-link them with `related` or merge if they describe one thing |
| Autologous stem cell transplant (high-dose therapy) | technology | "autologous stem cell transplant" is also Autologous stem cell transplant (ASCT) (autologous-transplant, term); cross-link them with `related` or merge if they describe one thing |
| Entity | Detail | |
|---|---|---|
| Aldoxorubicin | drug | name overlaps with Doxorubicin (doxorubicin) |
| Aminolevulinic acid (topical, for photodynamic therapy) | drug | name overlaps with 5-Aminolevulinic acid (oral, for glioma surgery) (aminolevulinic-acid-gleolan) |
| COMFORT-I | trial | name overlaps with COMFORT-II (comfort-ii) |
| Lipegfilgrastim | drug | name overlaps with Pegfilgrastim (pegfilgrastim) |
| Peginterferon alfa-2b | drug | name overlaps with Ropeginterferon alfa-2b (ropeginterferon-alfa-2b) |
| Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid Tumors | trial | name overlaps with A Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid Tumors (nct07136142) |
| Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical) | trial | name overlaps with A Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (IVOLGA) (nct06943833) |
| Tumour marker | term | name overlaps with Tumour markers (CEA, LDH, chromogranin, thyroglobulin) (tumour-markers) |
| Entity | Detail | |
|---|---|---|
| A Clinical Study to Evaluate the Safety of VIB305 in Patients With Advanced Solid Tumors | trial | no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record |
| A First-In-Human Trial of pTTL in Advanced Colorectal Cancer | trial | no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record |
| A First-in-Human, Phase 1/2 Study of LAT010 in Patients With Advanced Solid Tumors (LIGHTSPEED-1) | trial | no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record |
| A Modular Phase 1/2 Study With CT7439 in Participants With Solid Malignancies | trial | no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record |
| A Phase 1/2 Study of the Safety and Tolerability of MT-125 in GBM Patients | trial | no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record |
| A Phase I/II Clinical Study of CTS3497 in Patients With MTAP Deficient Malignacies | trial | no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record |
| A Phase I/II Clinical Study of WJ22096 Tablets in Patients With Advanced Tumors | trial | no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record |
| A Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, Immunogenicity, and Preliminary Efficacy of SGT003 in Patients With Advanced Solid Tumors | trial | no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record |
| A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of JL15003 Injection in Patients With Recurrent Glioblastoma (rGBM) | trial | no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record |
| A Phase IIa Study to Evaluate NBQ72S | trial | no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record |
| A Safety And Efficacy Study Of Allogeneic CAR Gamma-Delta T Cells in Subjects With Relapsed/Refractory Solid Tumors | trial | no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record |
| A Study Evaluating the Efficacy and Safety of ABP1011T Tablets in Patients With Advanced Solid Tumors | trial | no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record |
| A Study for HSK39775 in Participants With Solid Tumors | trial | no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record |
| A Study of ATTR-01 in Participants With Select Epithelial Solid Tumours | trial | no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record |
| A Study of GR1014 Cutaneous Gel for the Prevention of Skin Reactions Caused by Radiation Therapy for Breast Cancer | trial | no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record |
| A Study of HF1K16 Combined With Bevacizumab in Patients With Recurrent or Progressive Glioma | trial | no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record |
| A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer | trial | no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK201 in Participants With Advanced Solid Tumors | trial | no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record |
| A Study to Investigate Safety and Preliminary Efficacy of SOA101 in Adult Subjects With Advanced Solid Tumors | trial | no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record |
| A Trial of Vigil for Participants With Ovarian Cancer | trial | no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record |
| ACS BrightEdge (American Cancer Society) | company | no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record |
| AD1208 in Subjects With Any Progressive, Locally Advanced or Metastatic Solid Tumors | trial | no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record |
| Alexandria Venture Investments | company | no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record |
| Allogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) Patients | trial | no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record |
| An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia. | trial | no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record |
| An Open Label Dose Finding Study of PTT-4256 in Patients With Solid Tumours (RAISIC-1). | trial | no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record |
| An Open-label, First-in-Human, Dose-Escalation and Dose-Expansion Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPR1020 in Patients With Advanced Solid Tumors | trial | no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record |
| Andera Partners | company | no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record |
| Andreessen Horowitz Bio + Health | company | no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record |
| ARCH Venture Partners | company | no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record |
Generated 2026-09-28: 1024 products checked against openFDA labels, 5791 trials against ClinicalTrials.gov (status, phase, primary completion).
| Entity | Recorded | Registry | ||
|---|---|---|---|---|
| high | Trial status disagrees with ClinicalTrials.gov | Bonner trial (cetuximab plus radiotherapy) | positive | TERMINATED |
| high | Trial status disagrees with ClinicalTrials.gov | CLOCC | positive | TERMINATED |
| high | Trial status disagrees with ClinicalTrials.gov | CYTO-PV | positive | TERMINATED |
| high | Trial status disagrees with ClinicalTrials.gov | DESTINY-Lung01 | positive | TERMINATED |
| high | Trial status disagrees with ClinicalTrials.gov | KEYNOTE-057 | positive | TERMINATED |
| high | Trial status disagrees with ClinicalTrials.gov | ROCKstar | positive | TERMINATED |
| high | Trial status disagrees with ClinicalTrials.gov | TOWER | positive | TERMINATED |
| medium | Enrolment disagrees with ClinicalTrials.gov | A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) | enrolled 660 | enrolment 89 (actual) |
| medium | Enrolment disagrees with ClinicalTrials.gov | ABC-02 | enrolled 410 | enrolment 324 (actual) |
| medium | Enrolment disagrees with ClinicalTrials.gov | ACOSOG Z0011 (Alliance) | enrolled 891 | enrolment 605 (actual) |
| medium | Enrolment disagrees with ClinicalTrials.gov | AlphaBreak (FPI-2265) & AcTION (225Ac-PSMA-617) | enrolled 600 | enrolment 110 (actual) |
| medium | Enrolment disagrees with ClinicalTrials.gov | AMAROS (EORTC 10981-22023) | enrolled 1425 | enrolment 4813 (actual) |
| medium | Enrolment disagrees with ClinicalTrials.gov | AMPLIFY | enrolled 867 | enrolment 984 (actual) |
| medium | Enrolment disagrees with ClinicalTrials.gov | ARMOR3-SV | enrolled 38 | enrolment 953 (actual) |
| medium | Enrolment disagrees with ClinicalTrials.gov | ASCENT-03 | enrolled 558 | enrolment 623 (actual) |
| medium | Enrolment disagrees with ClinicalTrials.gov | ASTRA | enrolled 401 | enrolment 233 (actual) |
| medium | Enrolment disagrees with ClinicalTrials.gov | ATHENA-MONO / GOG-3020 | enrolled 538 | enrolment 1097 (actual) |
| medium | Enrolment disagrees with ClinicalTrials.gov | BLUE-C | enrolled 20176 | enrolment 26758 (actual) |
| medium | Enrolment disagrees with ClinicalTrials.gov | Bonner trial (cetuximab plus radiotherapy) | enrolled 424 | enrolment 32 (actual) |
| medium | Enrolment disagrees with ClinicalTrials.gov | BRF113928 cohort C (dabrafenib with trametinib, untreated BRAF V600E) | enrolled 36 | enrolment 177 (actual) |
| medium | Enrolment disagrees with ClinicalTrials.gov | C-144-01 | enrolled 153 | enrolment 220 (actual) |
| medium | Enrolment disagrees with ClinicalTrials.gov | CA184-043 | enrolled 799 | enrolment 988 (actual) |
| medium | Enrolment disagrees with ClinicalTrials.gov | CALGB/SWOG 80405 | enrolled 1137 | enrolment 2334 (actual) |
| medium | Enrolment disagrees with ClinicalTrials.gov | CAMBRIA-1 & CAMBRIA-2 | enrolled 10000 | enrolment 5511 (actual) |
| medium | Enrolment disagrees with ClinicalTrials.gov | CAPItello-291 | enrolled 708 | enrolment 818 (actual) |
| medium | Enrolment disagrees with ClinicalTrials.gov | CARTITUDE-1 | enrolled 97 | enrolment 126 (actual) |
| medium | Enrolment disagrees with ClinicalTrials.gov | CASPIAN | enrolled 805 | enrolment 987 (actual) |
| medium | Enrolment disagrees with ClinicalTrials.gov | Cemiplimab in basal cell carcinoma after a hedgehog inhibitor | enrolled 84 | enrolment 138 (actual) |
| medium | Enrolment disagrees with ClinicalTrials.gov | CheckMate 143 | enrolled 369 | enrolment 529 (actual) |
| medium | Enrolment disagrees with ClinicalTrials.gov | CheckMate 205 | enrolled 243 | enrolment 294 (actual) |
Where the registry value maps unambiguously onto ours, the fact check proposes a concrete edit. Nothing is applied automatically: a maintainer applies each proposed edit by hand, which updates the record, refreshes its checked date and adds a row to the corrections log.
Checked 2026-09-30: 32,546 of 32,546 cited URLs probed; 5855 did not resolve, 4616 redirect to a different domain, 579 have a Wayback Machine copy. Replace a dead URL with the archive copy or a current source; if the fact itself changes, log it in the corrections.
Records by last-checked date. The site does not show dates to readers; maintainers use this list to schedule re-checks. What counts as too old for each kind, and which records are past due, is defined on the freshness page.
Showing the 80 oldest of 19545. Full data: audit.json · factcheck.json · factcheck-patches.json · links.json · freshness · recent changes · corrections log.